Assessment of Residual Paralysis in Patients Who Receive Mini-dose Atracurium During Supraglottic Airway Insertion

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

337 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-02-29

Study Completion Date

2018-03-16

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to establish the incidence of residual paralysis in patients following administration of a mini- dose of atracurium (less than ED95 i.e. \<0.23mg/kg or \<15 mg in most patients) during supraglottic airway insertion and correlate it with the duration of time from drug administration to arrival at PACU. The secondary aim is to compare the incidence of residual paralysis in patients who receive full doses of atracurium (per body weight) with those who receive mini-doses.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Intubation Conditions With Atracurium After Three Minutes

NCT04808440

Obesity Female Patients Require General Anaesthesia With Intubation and Atracurium Curarization

COMPLETED

Emergence Agitation of Sevoflurane in Pediatric

NCT06830564

Emergence Delirium

COMPLETED PHASE2/PHASE3

Impact of Anesthetic Choice (Sevoflurane Versus Desflurane) on Airway Reflex Recovery in the Context of Antagonized Neuromuscular Block

NCT01199237

Airway Reflexes, Protective Recovery After Neuromuscular Block Anesthetic Recovery

COMPLETED PHASE4

Effect of Neuromuscular Blockade on Pulmonary Complications in Elective Cardiac Surgery

NCT02635542

Neuromuscular Blockade Postoperative Complications

COMPLETED PHASE4

Small Doses Muscle Relaxant in General Anesthesia

NCT04344262

Muscle Relaxant

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Post-operative residual paralysis may be defined as the incomplete recovery of muscle function following intra-operative administration of neuromuscular blockers (NMBs). This condition is associated with many negative patient outcomes such as: increased risk of aspiration; upper airway obstruction; and delayed Post-Anaesthetic Care Unit (PACU) discharge, amongst others. Despite the increasing use of shorter acting agents, the prevalence of residual paralysis in the PACU remains high at 20-50%. NMBs are commonly used to facilitate endotracheal intubation and insertion of the supraglottic airway by obtunding airway reflexes. Given the increasing use of mini-dose NMBs without post-operative reversal in clinical practice, there is a need to evaluate the incidence of residual paralysis in the patient population who have received mini-dose atracurium during the supraglottic airway insertion.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Postoperative Complications

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adults above 21 years old
* Received either a mini-dose of atracurium or full dose of atracurium during the placement of the supraglottic airway
* Did not receive any neuromuscular reversal agent at any point of the operation.

Exclusion Criteria

* Patients with underlying neuromuscular disease
* Patients who received pre-operative medication that may affect neuromuscular transmission
* Patients who required additional doses of neuromuscular blockade at any point of the operation

Minimum Eligible Age

21 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No